Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Remsima (infliximab) is administered intravenously; it is a medication used for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.
Fact Table | |
---|---|
Formula | C6428H9912N1694O1987S46 |
License | FDA approved |
Bioavailability | Not applicable (intravenous administration) |
Legal status | Prescription only |
Chemical Name | Infliximab |
Elimination half-life | Approximately 9.5 days |
Dosage (Strength) | 100 mg/vial |
Pregnancy | Consult a healthcare provider |
Brands | Remsima, Remicade, Inflectra |
Protein binding | Not extensively bound to plasma proteins |
PubChem CID | 16129606 |
MedlinePlus | a604000 |
ChEBI | 606143 |
ATC code | L04AB02 |
DrugBank | DB00065 |
KEGG | D02597 |
Routes of administration | Intravenous |
Your treatment plan will be decided by your doctor. Remsima will be administered via an IV infusion by your healthcare provider.
You may speak to your doctor if you have any questions or concerns about the medication.
Infliximab is the active ingredient contained in Remsima. Sucrose, polysorbate 80, sodium dihydrogen phosphate monohydrate, and disodium phosphate dihydrate are the inactive ingredients.
If you have any of the following, you should avoid Remsima treatment:
Some, but not all, side effects associated with Remsima treatment include infections, abnormal blood cell counts, allergic reactions, depression, trouble sleeping, headache, dizziness, rapid heart rate, blood pressure problems, stomach pain, nausea, liver problems, joint pain, muscle pain, and back pain. If you experience bothersome or persistent side effects, tell your doctor right away.
Talk to your doctor about Remsima injection.
Remsima. European Medicines Agency; 2018.